Independent BDs

When two agencies are probing your firm, it doesn’t hurt to ask that they coordinate their efforts.

Enforcement actions against IAs and reps at the state level soar in 2017, according to NASAA report.

LPL slammed the move by the exiting major issuer to cut off trails for advisors in certain existing contracts.

“High-touch” support, technology and firm culture played a part in career changes for seven advisors.

The practice transitioned in a week in which 15 advisors joined their new firm in three separate moves.

The No. 7 IBD expects such moves by advisors to increase in coming years, so it's ramping up offerings aimed at fee-only services.

Reg BI would boost sales because the products fill a pressing need for income over long lifespans, the executives say.

Allianz became the second multinational insurance firm to step away from the IBD space this year under a plan to shutter Questar Capital.

Schwab, Vanguard and LPL explained their approach to campaign donations as the industry and its supporting sectors provided $19 million in PAC contributions.

Sterne Agee changed its name after Stifel sold the firm in 2016 to INTL FCStone for about $50 million.

The private equity firm completed the largest IBD purchase of the year by acquiring the majority of the 7,700-advisor network.

Can FINRA suspend the advisor’s license?

Not all firms have procedures in place. Of those that do, about 20% aren’t enforcing them.

Being an independent advisor isn’t for everyone.

Dick Lampen says the SEC charges against Dr. Phillip Frost, the firm’s primary shareholder, won’t affect its “significant” other resources.

While the No. 1 IBD has retained a significant portion of the hybrid RIA’s advisors, its founder says the firm has major outside recruiting opportunities.

Gratz Park Private Wealth will offer internships and shadow programs to college women interested in business.

The advisors include the father, mother, daughter and son.

Charged with leading the firm’s recruiting and sales strategy, Scott Posner will report to the recent successor to Bill Morrissey, who left the firm last month.

While the IBD advocacy organization supports the proposal’s approach, key questions loom over the timeline and makeup of the potential regulation.